Focal therapy for prostate cancer: An unproven technique or a reasonable alternative to radical prostatectomy?
In order for a new treatment modality to be considered efficacious, it needs to be evaluated by acceptable criteria and demonstrate an improvement on the natural course of the disease. More »
Proton-beam Rx reduces prostate cancer recurrence
Prostate cancer patients administered high doses of proton-beam therapy appear to have a markedly reduced risk of disease recurrence when compared with other low-risk patients treated with conventional radiation therapy, according to two recent studies. More »
Early Breast and Prostate Cancer and Clinical Outcomes (Fracture)
Over 40 million men and women in the United States have osteoporosis and low bone mineral density (BMD), placing them at risk for adverse skeletal events such as fractures and their sequelae. There are over 12 million cancer survivors in this country. Of these, 22% were diagnosed with breast cancer and 17% with prostate cancer.[1,2] Because cancer therapies can adversely influence bone health, these survivors are at particular risk for skeletal complications. Cancer therapies associated with... More »
ECCO/ESMO study: Endocrine Rx for prostate cancer carries cardiovascular consequences
The first major study to address the cardiovascular adverse effects of endocrine therapy for prostate cancer could change attitudes toward treatment options because testosterone deprivation may have more impact on the patient’s life than it does on the androgen receptor. More »
Further Perspectives on Treating Localized Prostate Cancer
Standard treatment options for prostate cancer patients include surveillance, surgery, external-beam radiotherapy, brachytherapy, the combination of external-beam and brachytherapy, and the combination of radiotheraputic modalities with hormonal therapy, for appropriately chosen patients. More »
Active Surveillance for Low-Risk Localized Prostate Cancer
There is no universally accepted strategy for the screening, diagnosis, and treatment of prostate cancer. However, once a patient is diagnosed, his risk of cancer progression may be estimated using serum prostate-specific antigen (PSA), biopsy findings, and clinical stage. More »
Prostate cancer pilot program stresses patient-oriented care
The Association of Community Cancer Centers recently surveyed its members and found a universal request for assistance in developing prostate cancer care programs. The ACCC responded by setting up pilot programs in the U.S. that focus on the following areas: More »
Denosumab boosts bone mineral in prostate cancer
A phase III trial demonstrated that denosumab can reduce fracture risk in men with nonmetastatic prostate cancer undergoing androgen deprivation therapy, Amgen announced. More »
Shorter survival time seen in young prostate cancer patients
Young men with advanced forms of prostate cancer do not live as long as older men with similar forms of the disease, according to research conducted at the University of Washington in Seattle. More »
Localized Prostate Cancer: The Battle of Treatment Options Enters the Larger Arena
So here we go again with one more round in the battle of treatment options for localized prostate cancer. While more than 3 decades of such sparring has gotten us no closer to evidence-based conclusions, one might say that these matches do serve the purpose of bringing out the best and the worst of the therapeutic contenders. More »
Showing 1 - 10 of 230 results.
Page of 23
News & News Analysis

Duration of tamoxifen use influences cancer risk in opposite breast
Oncology NEWS International,  October 15, 2009
Low-risk tumors exhibit high proliferation index
Oncology NEWS International,  October 15, 2009
Bayer Taps New CEO
Oncology NEWS International,  October 15, 2009
Adjuvant Rx yields minor benefit in less aggressive colon cancer
Oncology NEWS International,  October 15, 2009
Low expression of MSH2 protein predicts survival in NSCLC
Oncology NEWS International,  September 29, 2009
Novel chemoRT regimen ups survival in pancreatic ca
Oncology NEWS International,  September 29, 2009
Prostate cancer pilot program stresses patient-oriented care
Oncology NEWS International,  September 29, 2009
Prostate cancer patients seek out mind-body care
Oncology NEWS International,  September 28, 2009
CT distinguishes liver cancer mets from lung primary
Oncology NEWS International,  September 28, 2009